Classifications: antimalarial; Therapeutic: antimalarial
Pregnancy Category: C
250 mg tablets
Antimalarial agent, structurally related to quinine.
Effective against all types of malaria, including chloroquine-resistant malaria.
Treatment of mild to moderate acute malarial infections, prevention of chloroquine-resistant malaria caused by Plasmodium falciparum and P. vivax.
Hypersensitivity to mefloquine or a related compound; with a calcium channel blocking agent, severe heart arrhythmias, history
of QTc prolongation; aggressive behavior; active depression, or history of depression, suicidal ideation; generalized anxiety
disorder, psychosis, schizophrenia, or other major psychiatric disorders; seizure disorders; pregnancy (category C); lactation.
Persons piloting aircraft or operating heavy machinery.
Route & Dosage
Note: FDA has NOT approved use of mefloquine in children, and the U.S. Public Health Service does NOT recommend its use in children <15
kg or in pregnant women
Treatment of Malaria
Adult: PO 1250 mg (5 tablets) as single oral dose taken with at least 8 oz of water
Child: PO 2030 mg/kg as single dose
Prophylaxis for Malaria
Adult: PO 250 mg once/wk x 4 wk (beginning 1 wk before travel), then 250 mg every other wk for duration of exposure
and for 2 doses after leaving endemic area
Child: PO 1519 kg, 1/4 tablet; 2030 kg, ? tablet; 3145 kg, ? tablet
- Give with food and at least 8 oz water.
- Do not give concurrently with quinine or quinidine; wait at least 12 h beyond last dose of either drug before administering
- Store at 15°30° C (59°86° F).
Adverse Effects (≥1%)Body as a Whole:
Arthralgia, chills, fatigue
, fever. CNS:
Dizziness, nightmares, visual disturbances, headache, syncope, confusion, psychosis, aggression, suicide ideation (rare). CV:
Bradycardia, ECG changes (including QTc
prolongation), first-degree AV block. GI:
Nausea, vomiting, abdominal pain, anorexia, diarrhea. Skin:
Diagnostic Test Interference
Transient increase in liver transaminases.
Mefloquine can prolong cardiac conduction in patients taking beta blockers
, calcium channel blockers
, and possibly digoxin. Quinine
may decrease plasma mefloquine concentrations. Mefloquine may decrease valproic acid
serum concentrations by increasing its hepatic metabolism. Administration with chloroquine
may increase risk of seizures. Increased risk of cardiac arrest and seizures with quinidine.
85% absorbed, concentrates in red blood cells. Onset:
59 and 28 h for parasite and fever clearance times in patients with P. vivax
infections, respectively; 166 and 93 h in patients with P. malariae
Concentrated in red blood cells due to high-affinity binding to red blood cell membranes; 98% protein bound; distributed
minimally into breast milk. Metabolism:
In liver. Elimination:
Primarily in bile and feces. Half-Life:
1021 d (shorter in patients with acute malaria).
Assessment & Drug Effects
- Monitor carefully during prophylactic use for development of unexplained anxiety, depression, restlessness, or confusion;
such manifestations may indicate a need to discontinue the drug.
- Evaluate cardiac and liver functions periodically with prolonged use.
- Lab tests: Monitor periodically CBC with differential during prolonged use.
- Monitor blood levels of anticonvulsants with concomitant therapy closely.
Patient & Family Education
- Take drug on the same day each week when used for malaria prophylaxis.
- Do not perform potentially hazardous activities until response to drug is known.
- Report any of the following immediately: Fever, sore throat, muscle aches, visual problems, anxiety, confusion, mental depression,